• Co-Diagnostics' Indian joint venture CoSara submitted its point-of-care tuberculosis test to India's CDSCO for regulatory clearance.
• Regulatory approval is expected in the fourth quarter of 2026, positioning CoSara for an Indian commercial launch before year-end.
• Clinical testing showed average sensitivity of 97.3% and specificity of 96% across three test batches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610270745PR_NEWS_USPR_____LA81682) on October 27, 2026, and is solely responsible for the information contained therein.